CGON (CG Oncology) Ending Cash Position: $19.64 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CGON CG Oncology Inc CGON
30 GF Score
Price $75.15
GF Value $139.19
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is CG Oncology Ending Cash Position?

CG Oncology CGON +0.36% 30 Ending Cash Position is $19.64 Mil as of Jun. 2026. GuruFocus rates CGON with a GF Score™ of 30/100 and a GF Value™ of $139.19 (Possible Value Trap). The stock has 6 warning signs investors should review.

CG Oncology's Ending Cash Position for the quarter that ended in Jun. 2026 was $19.64 Mil.

CG Oncology's quarterly Ending Cash Position increased from Dec. 2025 ($32.49 Mil) to Mar. 2026 ($33.70 Mil) but then declined from Mar. 2026 ($33.70 Mil) to Jun. 2026 ($19.64 Mil).

CG Oncology's annual Ending Cash Position increased from Dec. 2023 ($8.27 Mil) to Dec. 2024 ($257.07 Mil) but then declined from Dec. 2024 ($257.07 Mil) to Dec. 2025 ($32.49 Mil).

CG Oncology Ending Cash Position Related Terms

CG Oncology Ending Cash Position Historical Data

* Premium members only.

The historical data trend for CG Oncology's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CG Oncology Ending Cash Position Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
53.61 88.14 8.27 257.07 32.49

CG Oncology Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.62 45.15 32.49 33.70 19.64
CGON
30GF Score
CG Oncology Inc CGON
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CG Oncology Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

CG Oncology's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=257.068+-224.578
=32.49

CG Oncology's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=33.7+-14.064
=19.64

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $19.64 Mil mean?
CG Oncology (CGON) has a Ending Cash Position of $19.64 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on CG Oncology and its competitors.
Is CG Oncology's Ending Cash Position too high?
CG Oncology's current Ending Cash Position is $19.64 Mil. Overall, CG Oncology has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does CG Oncology's Ending Cash Position compare to LGND and XENE?
CG Oncology's Ending Cash Position of $19.64 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on CG Oncology and its competitors. CG Oncology's current Ending Cash Position is $19.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CG Oncology stock overvalued right now?
Based on GuruFocus' analysis, CG Oncology (CGON) is currently considered Possible Value Trap. The stock's GF Value™ is $139.19, compared to a current price of $75.15 — trading 46% below its estimated fair value. The current Ending Cash Position is $19.64 Mil. CG Oncology's overall GF Score™ is 30/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For CG Oncology (CGON), the current Ending Cash Position is $19.64 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CG Oncology (CGON) Overvalued in 2026?

Based on GuruFocus' analysis, CG Oncology stock appears to be undervalued. The current stock price of $75.15 is trading 46% below its estimated GF Value™ of $139.19. GuruFocus considers CG Oncology to be Possible Value Trap.

Key valuation signals for CGON:

  • Ending Cash Position: $19.64 Mil
  • GF Value™: $139.19 vs. price of $75.15 (46% below fair value)
  • GF Score™: 30/100 with 6 warning signs

No single metric tells the full story. See the CGON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CG Oncology Business Description

Address 400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
30GF Score

Get the complete analysis for CGON

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$75.15
Price
$139.19
GF Value